Logo image of CMPX

COMPASS THERAPEUTICS INC (CMPX) Stock Fundamental Analysis

NASDAQ:CMPX - US20454B1044 - Common Stock

3.49 USD
0 (0%)
Last: 8/29/2025, 8:13:54 PM
3.43 USD
-0.06 (-1.72%)
After Hours: 8/29/2025, 8:13:54 PM
Fundamental Rating

3

Overall CMPX gets a fundamental rating of 3 out of 10. We evaluated CMPX against 542 industry peers in the Biotechnology industry. CMPX has a great financial health rating, but its profitability evaluates not so good. CMPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CMPX has reported negative net income.
CMPX had a negative operating cash flow in the past year.
CMPX had negative earnings in each of the past 5 years.
In the past 5 years CMPX always reported negative operating cash flow.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.31%, CMPX is in line with its industry, outperforming 56.64% of the companies in the same industry.
With a decent Return On Equity value of -52.97%, CMPX is doing good in the industry, outperforming 64.76% of the companies in the same industry.
Industry RankSector Rank
ROA -42.31%
ROE -52.97%
ROIC N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

CMPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CMPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CMPX has more shares outstanding than it did 1 year ago.
CMPX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CMPX has an Altman-Z score of 9.84. This indicates that CMPX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CMPX (9.84) is better than 86.53% of its industry peers.
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.84
ROIC/WACCN/A
WACC9.86%
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 7.66 indicates that CMPX has no problem at all paying its short term obligations.
CMPX has a Current ratio of 7.66. This is in the better half of the industry: CMPX outperforms 72.69% of its industry peers.
A Quick Ratio of 7.66 indicates that CMPX has no problem at all paying its short term obligations.
The Quick ratio of CMPX (7.66) is better than 73.06% of its industry peers.
Industry RankSector Rank
Current Ratio 7.66
Quick Ratio 7.66
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CMPX have decreased strongly by -21.62% in the last year.
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 30.24% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 232.42% on average over the next years. This is a very strong growth
EPS Next Y-47.13%
EPS Next 2Y-24.68%
EPS Next 3Y-9.87%
EPS Next 5Y30.24%
Revenue Next Year-100%
Revenue Next 2Y421%
Revenue Next 3Y356.71%
Revenue Next 5Y232.42%

3.3 Evolution

CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPX. In the last year negative earnings were reported.
Also next year CMPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as CMPX's earnings are expected to decrease with -9.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.68%
EPS Next 3Y-9.87%

More info and screens

0

5. Dividend

5.1 Amount

CMPX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (8/29/2025, 8:13:54 PM)

After market: 3.43 -0.06 (-1.72%)

3.49

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners55.88%
Inst Owner Change-0.61%
Ins Owners8.55%
Ins Owner Change0.41%
Market Cap598.78M
Analysts88.75
Price Target13.46 (285.67%)
Short Float %6%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.34%
Min EPS beat(2)-10.69%
Max EPS beat(2)-5.99%
EPS beat(4)1
Avg EPS beat(4)1.05%
Min EPS beat(4)-10.69%
Max EPS beat(4)30.79%
EPS beat(8)3
Avg EPS beat(8)5.47%
EPS beat(12)5
Avg EPS beat(12)6.98%
EPS beat(16)8
Avg EPS beat(16)-2.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.13%
PT rev (3m)12.82%
EPS NQ rev (1m)-9.47%
EPS NQ rev (3m)-35.56%
EPS NY rev (1m)-6.44%
EPS NY rev (3m)-13.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 704.45
P/FCF N/A
P/OCF N/A
P/B 6.42
P/tB 6.42
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.31%
ROE -52.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.11%
Cap/Sales 7.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.66
Quick Ratio 7.66
Altman-Z 9.84
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)12.9%
Cap/Depr(5y)74.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-47.13%
EPS Next 2Y-24.68%
EPS Next 3Y-9.87%
EPS Next 5Y30.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y421%
Revenue Next 3Y356.71%
Revenue Next 5Y232.42%
EBIT growth 1Y-12.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.87%
EBIT Next 3Y-10.87%
EBIT Next 5Y20.26%
FCF growth 1Y-2.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.01%
OCF growth 3YN/A
OCF growth 5YN/A